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TO THE EDITOR—We read the article by Fraaij et al [1] and would like to summarize the 
available information on intravenous zanamivir from the Food and Drug Administration 
(FDA)’s Emergency Investigational New Drug (EIND) application process [2]. No 
intravenous antiviral agents for treatment of severe influenza are currently approved in the 
United States. Since the emergence of 2009 pandemic influenza A virus subtype H1N1 
(A[H1N1]pdm09), intravenous zanamivir has been authorized through an EIND application 
to the FDA as an investigational treatment for patients with serious and life-threatening 
influenza. As part of the EIND process, treating physicians are encouraged to submit data to 
the FDA, but reporting of requested data is voluntary. We reviewed the FDA’s EIND 
database on influenza patients who received intravenous zanamivir from April 2009 through 
April 2011. For the 200 patients identified, we performed a descriptive analysis of reported 
patient information on age, sex, pregnancy status, baseline comorbidities, virologic test 
results, antiviral resistance data, other antiviral treatments, clinical complications, supportive 
care modalities used, intravenous zanamivir treatment duration, adverse events (AEs), and 
outcomes (Table 1).
At the time of intravenous zanamivir request, many patients were critically ill with 
underlying comorbidities and required intensive care unit admission for severe 
complications of influenza A virus infection (predominantly due to A[H1N1]pdm09), 
including respiratory failure and renal failure. Most patients (78.5%) had received prior or 
concomitant antiviral agents, mainly oseltamivir, although some (10%) had also received 
intravenous peramivir. Nine percent of patients (mostly with comorbidities and/or 
immunosuppression) had documented oseltamivir resistance associated with the H275Y 
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mutation in viral neuraminidase, and overall approximately 25% of intravenous zanamivir 
requests were for patients with confirmed or clinically suspected oseltamivir resistance. 
Other published case series of A(H1N1) pdm09-infected patients have reported fewer 
complications at the time of intravenous zanamivir initiation and fewer reports of oseltamivir 
resistance [1, 3-7].
Our findings have several important limitations. First, almost no microbiologic data were 
provided in cases in which patient narratives reported pneumonia or bacterial coinfection. In 
69 of 73 cases reporting pneumonia, microbiologic or additional clinical data were not 
available to determine whether cases of pneumonia represented secondary bacterial infection 
or primary influenza virus pneumonitis. In 4 pneumonia cases, methicillin-resistant 
Staphylococcus aureus (MRSA) infection (in 3 cases) or Pneumocystis jirovecii infection (in 
1 case) was reported. In 15 of 19 cases reporting bacterial coinfection, microbiologic or 
additional clinical data were not provided to delineate the source (eg, blood, urine, skin, 
central nervous system, or catheter related), etiology, or severity of the bacterial infection. 
Four cases had microbiologic or clinical information in which MRSA bacteremia (in 3 
cases) or Streptococcus pyogenes skin and soft-tissue infection (in 1 case with concomitant 
burns) was reported. Second, limited outcome, follow-up, or adverse event data were 
reported. Third, interpretation of data is limited by the retrospective and uncontrolled design 
to assess differences in data reported (eg, clinical outcomes, microbiologic data, diagnostic 
data, and adverse events).
Most intravenous zanamivir EIND authorizations were for late treatment of critically ill 
adult patients with A(H1N1) pdm09 infection, including a subset with confirmed or 
suspected oseltamivir resistance. It is possible that cases of oseltamivir resistance could 
increase in the future [8, 9]. However, conclusions regarding the clinical effectiveness or 
safety of intravenous zanamivir for treatment of critically ill influenza patients cannot be 
drawn from these data; randomized clinical trials are needed and are ongoing [10].
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